Biopharmaceutical start-ups brought in 19% less funding in the first quarter of 2017 as compared with the previous quarter, but venture capital investors placed big bets on a few new companies, including a $150m Series A round for Vir Biotechnology Inc. helmed by Biogen's former CEO.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?